UNIVERSITY OF SOUTHERN CALIFORNIA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
Clinical Trials
748
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (621 trials with phase data)• Click on a phase to view related trials
MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 130
- Registration Number
- NCT07162194
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Hyperemesis Gravidarum Risk Reduction With Metformin
- Conditions
- Hyperemesis Gravidarum
- Interventions
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 224
- Registration Number
- NCT07129473
Novel Multimodal Neural, Physiological, and Behavioral Sensing and Machine Learning for Mental States
- Conditions
- No ConditionStudy Mental State in Healthy Populations and Drug-resistant Epilepsy Patients With Existing iEEG
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 90
- Registration Number
- NCT07110688
- Locations
- 🇺🇸
Rancho Los Amigos National Rehabilitation Center, Downey, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Precision Performance Status Compared With ECOG Performance Status
- Conditions
- Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 41
- Registration Number
- NCT07082257
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
- Conditions
- Breast Carcinoma
- First Posted Date
- 2025-07-21
- Last Posted Date
- 2025-07-21
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 150
- Registration Number
- NCT07076147
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 150
- Next
News
Adagene's Masked Anti-CTLA-4 Therapy ADG126 Shows 30% Response Rate in Treatment-Resistant Colorectal Cancer
Adagene's ADG126, a masked anti-CTLA-4 therapy, achieved a ~30% objective response rate with durable responses in microsatellite stable colorectal cancer patients who had failed previous treatments.
Semaglutide Shows Promise in Reducing Cocaine Addiction in Preclinical Study
Researchers at the University of Gothenburg found that semaglutide, a diabetes and weight loss medication, reduced cocaine self-administration by 26% in rats compared to control animals.
NeOnc Technologies Receives FDA Authorization for Phase II Brain Cancer Trial of NEO212
NeOnc Technologies received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer.
Fertility Preservation Gains Momentum in Cancer Care as Awareness and Access Improve
Cancer treatments including chemotherapy, radiation therapy, and surgery can severely impact fertility in reproductive-age patients, making early fertility preservation counseling essential.
FDA Expert Panel Calls for Revision of Menopausal Hormone Therapy Warning Labels
An FDA expert panel convened to reassess boxed warnings for menopausal hormone therapy, with multiple experts arguing that current labels overstate risks and are not supported by comprehensive scientific evidence.
NeOnc Technologies Secures $50 Million Investment to Expand Brain Cancer Clinical Trials in MENA Region
NeOnc Technologies signed a non-binding term sheet with Quazar Investment for a $50 million equity investment to establish a UAE-based clinical platform focused on the Middle East and North Africa region.
Mendaera's Focalist Handheld Robotic System Receives FDA Clearance for Ultrasound-Guided Procedures
Mendaera received FDA 510(k) clearance for its Focalist handheld robotic system designed to enhance precision in ultrasound-guided needle placement procedures.
Maternal Cardiometabolic Risk Factors During Pregnancy Linked to Higher Blood Pressure in Children
A recent study published in JAMA Network Open reveals that maternal obesity, gestational diabetes, and hypertensive disorders during pregnancy are associated with elevated blood pressure in offspring.
NeOnc Technologies to List on Nasdaq Global Market with Novel Blood-Brain Barrier Therapeutics
NeOnc Technologies Holdings, Inc. will begin trading on the Nasdaq Global Market under the ticker symbol "NTHI" on March 26, 2025, following SEC approval of its registration statement.
American Cancer Society Unveils Strategic Vision: $517M Research Initiative Focuses on Early Detection and Diversity
The American Cancer Society (ACS) has committed $517 million to research grants, with a significant focus on supporting early-career investigators and promoting diversity in cancer research.